FDA Puts Aging on Its Regulatory Science Agenda — What That Actually Means
The FDA added aging to its regulatory science agenda. It signals seriousness about longevity but creates no new trial pathway or approval. What it does mean.
Peter Attia's Framework for Prioritizing Health Interventions — What's High-Impact vs. Optimization
Peter Attia separates foundation interventions (exercise, sleep, nutrition) from optimizations like supplements, judged by effect size and trade-offs.
The Longevity Biotech 100x Return Is Real — But It's Social Value, Not Investor Profit
A model puts $366.8 trillion of social value on therapies adding 10 years of life, against $3.3 trillion in costs. Why that 100x isn't an investor return.
Oura Ring Just Connected to Xella's Women's Health Platform — This Is What Clinical Interpretation of Wearable Data Actually Looks Like
Xella now pulls Oura Ring sleep, HRV, and temperature data into clinical interpretation alongside hormone tests, covering 130+ female-specific conditions.
Peter Attia on Thyroid Health: Why 5% of Adults Are Mismanaged, TSH Isn't the Full Picture, and What to Do When Tests Look Normal But You Don't
In AMA #89, Peter Attia addresses thyroid dysfunction — one of medicine's most commonly mismanaged conditions. TSH measures pituitary signaling, not tissue-level T3 activity. He stakes out the messy middle between under-treatment and over-treatment camps, with a framework for evaluating subclinical dysfunction and persistent symptoms with normal tests.
Ultrahuman's HealthEx PowerPlug Maps 532 Medical Conditions to Your Ring Data — And Generates Doctor-Ready Visit Summaries
Ultrahuman's HealthEx PowerPlug integrates electronic medical records with Ring biomarker data — mapping 532 conditions, medications, and procedures to a unified timeline alongside heart rate, HRV, skin temperature, and sleep. Launches at $4.99/month or $45.99/year; HealthEx Wallet remains free.
Yale Tested 51 Antiaging Interventions. Only 13 Actually Worked.
A Yale University-led study published in Nature Medicine analyzed 51 human intervention studies across 3,128 blood samples using 16 epigenetic clocks and 94 DNA methylation biomarkers. Result: 51% of interventions showed no significant epigenetic age change. Senolytics failed. Anti-TNF therapies and Mediterranean diet protocols produced genuine, reproducible effects.
Apple Watch Series 12 Can Now Estimate Your Biological Age. Here's What It Actually Measures.
Apple Watch's new Longevity tab introduces a Health Age metric built from VO2 max, resting heart rate, sleep quality, and HRV — plus optional lab inputs. The hardware update delivers 24x faster HRV refresh and splits HRV into two clinically distinct signals.
Screens Aren't Causing the Myopia Epidemic. The Real Culprit Is What They're Replacing.
Peter Attia reviews the evidence on rising nearsightedness rates and finds screens are a weak causal factor — the real driver is reduced outdoor time and the loss of bright-light exposure that comes with it. 90–120 minutes outside daily is the most evidence-backed intervention.
Mito Health Hits 1 Million Lab Tests — and the $9 Membership Model Is Why It Matters
Mito Health, the direct-to-consumer diagnostics platform, has processed over 1 million lab tests at cost with a $9/month flat-fee membership. The milestone marks a shift in how serious longevity practitioners access biomarker data — no insurance, no referrals, no per-test markup.
Blood Pressure and Longevity: What Peter Attia's AMA #48 Gets Right About Measurement
Blood pressure is one of three primary drivers of atherosclerosis — yet most people check it once a year. Attia's AMA #48 rebroadcast makes the case for treating it as a daily metric.
Zone 2 Training: Why Time-Constrained Athletes May Be Better Off Skipping It
Peter Attia reframes Zone 2 as a volume tool, not a metabolic must-do — and the implications for busy people are bigger than expected.
Insilico Medicine's 287% Revenue Jump: AI Drug Discovery Is Becoming Real Pharma Revenue
Insilico Medicine grew to $106M revenue in H1 2026 on $7.3B in total deal value with Eli Lilly, Servier, and others — and a 90% gross margin that confirms AI drug pipelines have crossed from research promise to commercial scale.
Oura Health Files for IPO at $16 Billion: What a Smart Ring's Valuation Tells Us About Biometric Data
Oura Health is targeting a $3B raise at a $16B valuation — a 45% jump from 18 months ago — built on a hardware-plus-subscription model that turns sleep and recovery data into recurring revenue.
Mount Sinai's $1M XPRIZE Bet: Can the Immune System Be Reset to Fight Aging?
Mount Sinai secured $1M in XPRIZE Healthspan funding to run NYC-Vita, a trial combining lifestyle and medication to restore immune function decades lost to aging.
Quest Diagnostics Is Now Selling Biological Age: What the $29 Test Actually Measures
Humanity's biological age test is now a $29 add-on at 2,000 Quest locations. The model behind it tracked 306,000+ people for 11.6 years and covers six body systems.
KardiaMobile 6L: The Study That Found Twice as Many Arrhythmias as Hospital Monitors
A University of Rochester cohort study published in JACC Advances found AliveCor's KardiaMobile 6L detected nearly twice the arrhythmia rate of traditional short-duration ECG monitors in 350 patients over 30 days.
Gum Recession: Why the Habits You Think Are Helping May Be Hurting
Gum recession affects 88% of adults 65+, and aggressive brushing is a leading cause. Why lost gum tissue never grows back — and the one technique change that matters.
Tru Niagen at GNC and Sam's Club Signals NAD+ Has Left the Longevity Niche
The number one NAD+ supplement in the US is now in nearly 300 retail locations across 44 states. What the GNC and Sam's Club expansion says about where the longevity market is heading.
Whole-Body MRI Is Leaving the Biohacker Bubble
EHE Health's partnership with Prenuvo brings whole-body MRI screening into 200+ preventive care clinics. What this transition from biohacker niche to medical infrastructure means for longevity-minded members.
Wonderfeel: What a 4,235% Growth Rate Signals for the NAD+ Supplement Market
The NAD+ longevity brand ranked No. 1 biotech on the 2026 Inc. 5000. The growth rate reflects a consumer longevity market that's moving faster than most industry observers expected.
Can AI Put the Cell Back Together? GenBio's Virtual Cell Model Tries
GenBio AI's AIDO Cell system creates a stateful virtual cell model — integrating DNA, RNA, and protein behavior — to predict how intervention sequences affect biological aging.
Function Health's AI Connector: Your Lab Results Just Became AI Training Data — For You
Function's new connector links 160+ personal lab results to ChatGPT, Claude, and Perplexity. Over 80% of members have at least one biomarker outside optimal range — now AI can reason over that directly.
GDF-15 and P-Tau217: The Biomarkers That Warn You Before You Feel Anything
New biomarker research is shifting the question from 'what's wrong?' to 'what's coming?' GDF-15 as a cellular stress signal and p-tau217 for pre-symptomatic Alzheimer's risk represent a new category of early detection — but their limitations matter as much as their promise.